Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib as second-line treatment for advanced recurrent cervical cancer
ChiCTR-OIN-17012164Phase 2Completed
- Sponsor
- Zunyi Medical University Affiliated Hospital
- Start
- Jul 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rivoceranib in Cervical Cancer (CC) (2 arms), sponsored by Zunyi Medical University Affiliated Hospital. Primary endpoints: progression-free survival, overall survival and 1 more. Started Jul 2017; status: completed.
02
Drugs
Rivoceranib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR-OIN-17012164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIN-17012164.